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Abstract
Introduction: The aim of this study was to determine patient-perceived characteristics of 
Chronic Obstructive Pulmonary Disease (COPD) in patients participating in a large trial evaluating 
tiotropium bromide.
Patients and methods: Baseline symptoms were assessed by means of a standardized 
questionnaire. Patients reported symptoms that led to diagnosis as well as their current most 
troublesome symptom.
Results: Data were obtained from 298 patients, mostly male (95 %), with mean (standard deviation) 
baseline forced expiratory volume in 1 second of 1.1 (0.4) L (40.6 [13.3] % of predicted), mean 
disease duration of 14.4 (10.1) years and smoking history of 55.1 (25.3) pack-years. Dyspnoea 
was the most frequently reported symptom leading to COPD diagnosis (55.0 % of patients), 
followed by cough (33.2 %). Dyspnoea was also the current most troublesome symptom (82.6 %), 
followed by cough (8.4 %). The presence of dyspnoea or cough was independent of COPD severity. 
The most commonly reported co-morbidities were cardiovascular disorders (49 % of patients), 
gastrointestinal disorders (20 %) and metabolic disorders (16 %), mainly diabetes mellitus.
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Conclusions: This analysis confi rms the importance of dyspnoea as the most common symptom 
leading to initial COPD diagnosis and the symptom most troublesome to patients. Co-morbidities 
are common among COPD patients, and hence spirometric testing is appropriate in a patient 
who presents with dyspnoea associated with such a condition.
© 2010 Published by Elsevier España, S.L. on behalf of Sociedade Portuguesa de Pneumologia. 
All rights reserved.
A importância da dispneia no diagnóstico da doença pulmonar obstrutiva crónica — 
uma análise descritiva de uma coorte estável em Portugal (ensaio clínico SAFE)
Resumo
Introdução: Este estudo teve como objectivo determinar os principais sintomas percepcionados 
pelos doentes com doença pulmonar obstrutiva crónica (DPOC) numa coorte de doentes que 
participaram num grande ensaio clínico, que avaliou o tiotrópio e que decorreu em Portugal.
População e métodos: A caracterização dos sintomas, no momento de avaliação basal dos 
doentes foi efectuada através do recurso a um questionário padronizado. Os doentes foram 
inquiridos quanto aos principais sintomas que tinham levado ao diagnóstico e também quanto ao 
sintoma actual mais problemático.
Resultados: Os resultados foram obtidos de 298 doentes, maioritariamente masculinos (95 %), 
que apresentavam, uma média (desvio padrão) de volume expiratório forçado no primeiro 
segundo basal de 1,1 (0,4) L (40,6 [13,3] % do valor preditivo), uma duração média da doença de 
14,4 (10,1) anos e uma carga tabágica de 55,1 (25,3) Unidades Maço Ano. A dispneia foi o sintoma 
mais frequentemente reportado, como tendo sido o sintoma que levou ao diagnóstico da doença 
(55,0 % de doentes), seguindo-se-lhe a tosse (33,2 %). A dispneia foi também o síntoma actual 
mais problemático (82,6 %), seguindo-se-lhe também a tosse (8,4 %). A presença de dispneia ou 
tosse foi independente da gravidade da DPOC. As comorbilidades mais frequentemente 
reportadas foram as doenças cardiovasculares (49 % dos doentes), gastrointestinais (20 %) e 
metabólicas (16 %), principalmente a diabetes mellitus.
Conclusões: Esta análise confi rma a importância da dispneia como o sintoma mais comum que 
leva ao diagnóstico inicial da DPOC e o sintoma actual mais problemático para os doentes. As 
comorbilidades são comuns entre os doentes com DPOC, pelo que a espirometria deve ser 
realizada nos doentes que apresentem dispneia associada às patologias mais frequentes.
© 2010 Publicado por Elsevier España, S.L. em nome da Sociedade Portuguesa de Pneumologia. 
Todos os direitos reservados.
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Introduction
Chronic obstructive pulmonary disease (COPD) is increasingly 
recognized as a major public health challenge. 1 COPD is 
characterised by reduced expiratory airfl ow that is commonly 
associated with symptoms of cough, sputum production and 
dyspnoea. 2 Accurate symptom characterisation of patients 
in all stages of severity is an important step in diagnosis and 
treatment.
According to the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) guidelines, 3 diagnosis and severity of 
COPD is defined by lung function parameters. Despite a 
well-known clinical characterisation of the disease, more 
knowledge is needed about the natural history of symptoms 
and smoking status according to the different degrees of 
disease severity.
This study aimed to fi nd out the main patient-perceived 
characteristics of COPD by disease severity that led to the 
diagnosis among patients participating in a clinical trial 
evaluating tiotropium bromide. The aim of this subanalysis 
was to identify the most frequent and most troublesome 
symptoms.
Patients and methods
Study Design
Three hundred and eleven COPD patients were studied 
in a clinical trial evaluating tiotropium bromide, entitled 
SPIRIVA Assessment of Forced Expiratory volume in 1 second 
(SAFE; trial #205.282). This trial was a prospective, 
multicentre, randomized, double-blind, placebo-controlled 
parallel-group study designed to determine whether the 
effect on lung function of inhaled tiotropium 18 g once 
daily over 12 weeks was affected by smoking status, 4 where 
thirty-one Portuguese respiratory centres participated. 
The trial was approved by each local ethics committee and 
institutional review board. All patients provided written 
informed consent prior to the initiation of any study-related 
procedure.
The primary endpoint was change in trough forced 
expiratory volume in 1 second (FEV1) after 12 weeks of 
treatment. 4
During the screening visit, evaluation of patients 
included the collection of each patient’s demographic 
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data, medical and smoking histories, concomitant 
diagnoses and therapies and a physical examination, 
including lung function tests.
The study groups consisted of outpatients of either sex 
who were aged ≥ 40 years and had a clinical diagnosis of 
COPD, as defi ned by the American Thoracic Society (ATS). 5 
Participants were required to have at least a 10 pack-year 
smoking history, clinically stable airway obstruction and 
moderate or severe COPD, as defi ned by a pre-bronchodilator 
FEV1 ≤ 70 % of predicted normal values and a FEV1/forced 
vital capacity (FVC) ≤ 70 %. This defi nition of COPD severity 
was according to the current GOLD guidelines, when the 
study was designed (2002), 3 where pre-bronchodilator rather 
than post-bronchodilator FEV1 values were used. Patients 
were not included if they were considered to be at risk of 
COPD (defi ned as having normal lung function associated 
with cough and sputum production), again per the GOLD 
recommendations dated on 2002. 3 Other exclusion criteria 
were a history of asthma, allergic rhinitis, atopy, recent 
history (6 months or less) of myocardial infarction, unstable 
arrhythmia or any clinically signifi cant disease that might put 
the patient at risk because of study participation. Patients 
with ≥ 3 exacerbations of COPD in the preceding year or 
an exacerbation or lower respiratory tract infection within 
the 6 weeks prior to randomization were also excluded. 
Patients also should not have received prior treatment with 
tiotropium.
Symptom assessments
In this analysis, two COPD symptom measures were assessed: 
the fi rst symptom that led to COPD diagnosis and the most 
current troublesome symptom.
Regarding the fi rst symptom that led to COPD diagnosis, 
this was taken from patients’ charts, where past clinical 
history was described.
The most troublesome symptom currently, including 
wheezing, shortness of breath (dyspnoea), cough and 
tightness of the chest, was evaluated by means of a 
standardized questionnaire at randomization (see online 
appendix for supplementary details). Each investigator 
completed this form, which provided an assessment of 
the patient’s symptoms, based on the patient’s condition 
during the week prior to giving the information of the most 
troublesome symptom. In this assessment, the severity of 
each symptom was rated as mild (awareness of symptom, 
which was easily tolerated), moderate (causing suffi cient 
discomfort to cause interference with usual activity) or 
severe (incapacitating, with inability to work or perform 
usual activity). Symptom assessments were performed 
before spirometric testing.
Spirometric testing
Baseline measurements were recorded between 07:00 and 
10:00 AM, 2 weeks prior to randomization. Spirometric 
manoeuvres were conducted in triplicate and the highest 
FEV1 and FVC values were recorded. Measurements were 
performed in a Datospir 120C spirometer (Sibelmed, 
Barcelona, Spain) in accordance with ATS criteria. 6 Predicted 
normal values for FEV1 and FVC were derived from standard 
equations. 7
Statistical analysis
Data analysis was based on the patient cohort included 
in the primary study analysis. Oracle clinical was used to 
manage the data and statistical analysis was performed 
using SAS software (SAS Institute, version 8.2). A descriptive 
analysis of the patients according to the questionnaire 
was performed. Data are presented as mean and standard 
deviation (SD). Statistical comparisons used the Student 
t test for parametric data, Mann Whitney U tests for 
nonparametric data, and x 2 test for descriptive data. A 
P < 0.05 was considered signifi cant.
Results
Atotal of 311 patients from 31 study sites were randomized 
to treatment. A further 13 patients were excluded from the 
analysis after randomization due to the following reasons: 
7 changed their smoking status during the study and 6 did 
not fulfil the inclusion criteria when reassessed at the 
baseline visit. Hence, 298 patients were included in the 
analysis according to severity at baseline (Table 1). Patients 
were mostly male and had moderate to very severe COPD, 
as defi ned by the GOLD stages but using pre-bronchodilator 
FEV1 values.
Dyspnoea was the most frequently reported symptom that 
led to COPD diagnosis in 55.0 % of patients. It was also the 
most frequently reported symptom leading to diagnosis in 
every disease stage, except in the moderate stage, where 
dyspnoea and cough were equally prevalent (Fig. 1). With 
regards to the current most troublesome symptom reported 
by patients across all subgroups of severity, dyspnoea was 
also the most commonly reported symptom, being reported 
by 82.6 % of patients (Fig. 2). Cough was the second most 
frequently reported symptom leading to diagnosis (in 33.2 % 
of patients) (Fig. 1) and also the second currently most 
troublesome symptom (8.4 %) (Fig. 2). In the moderate 
disease severity group, the frequency of cough and dyspnoea 
was equal at the time of diagnosis, as referred above 
(Fig. 1). However, when compared with dyspnoea, cough 
had an inverse frequency pattern (Fig. 2), if disease severity 
is taken into account. It is worth noting that only 5.0 % of 
patients reported sputum production as the fi rst symptom 
that led to the diagnosis (Fig. 1).
Concerning the severity of symptoms at baseline, 
dyspnoea was mild or moderate in 75.9 % of patients; cough 
was mild or moderate in 64.3 % of patients and wheezing in 
53.0 % of patients (Table 2).
There was no statistically signifi cant association between 
smoking status (current versus past smokers) and the fi rst 
symptom leading to diagnosis (P = .699) or to the most 
troublesome symptom (P = .554).
Similarly, there was also no statistically significant 
association between body mass index (BMI) and the first 
symptom leading to diagnosis (P = .80) or to the most 
troublesome symptom (P = .336).
Almost half (49 %) of the patients enrolled in the 
study had a cardiovascular condition in the last 5 years, 
and this was the most frequent concomitant diagnosis 
(co-morbidity), followed by gastrointestinal disease (20 %) 
and metabolic-endocrine conditions (16 %) (Fig. 3). Among 
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the group of cardiovascular, arterial hypertension was the 
most frequent, being present in 88 % of the global group 
of patients. In the gastrointestinal disease group, 85 % had 
peptic disease, and in the metabolic disorders group 53 % 
had diabetes mellitus. Concomitant pulmonary disorders 
were reported in 14 % of patients (n = 48). Of these 14 had 
diagnosis of obstructive sleep apnea syndrome or past 
tuberculosis (n = 8), and 26 had a diagnosis that could be 
considered a COPD complication: pneumonia (n = 13), COPD 
Table 1 Demographics and baseline data
 Moderate Severe Very severe Total
No. of patients 81 142 75 298
Males (%) 90  99 96  96
Age (years)a 64.5 (9.8)  66.1 (8.3) 63.2 (8.5)  64.9 (8.9)
Duration of COPD (years)a 13.4 (10.8)  14.8 (10.4) 13.7 (8.8)  14.4 (10.1)
Smoking history (pack-years)a 56.7 (25.1)  54.0 (25.2) 55.6 (26.0)  55.1 (25.3)
Current smoker (%) 23 (28.4)  38 (26.8) 14 (18.7)  75 (25.2)
FEV1 (L)a  1.6 (0.3)   1.1 (0.2)  0.7 (0.1)   1.1 (0.4)
FEV1 (% predicted)a 57.7 (6.4)  39.3 (5.6) 24.5 (4.0)  40.6 (13.3)
FVC (L)a  3.0 (0.7)   2.5 (0.6)  2.0 (0.5)   2.5 (0.7)
FEV1/FVC (%)a 53.2 (9.2)  44.6 (9.4) 36.6 (9.5)  44.9 (11.1)
BMI (kg/m 2)a 27.3 (5.1)  26.9 (5.2) 24.4 (4.4)  26.4 (5.1)
Visits to emergency room in previous 12 monthsa  0.5 (1.2)   0.6 (2.3)  1.1 (3.0)   0.7 (2.3)
Courses of antibiotic  0.84 (0.98)   1.01 (1.21)  1.25 (1.56)   1.02 (1.26)
Courses of steroids  0.33 (0.94)   0.39 (0.83)  0.85 (2.51)   0.49 (1.47)
BMI: body mass index; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 second; FVC: forced vital 
capacity.
 aValues expressed as mean (SD).
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Figure 1 Distribution of patient-perceived symptoms leading to initial diagnosis of COPD by disease severity.
Table 2 Severity of COPD symptoms at baseline (% of 
patients)
 Not present Mild Moderate Severe
Wheezing 45.0 39.5 13.5 1.9
Dyspnoea 17.7 40.5 35.4 6.4
Cough 33.4 48.2 16.1 2.3
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exacerbations (n = 4), pneumothorax (n = 4), bronchiectasis 
(n = 3), pulmonary thromboembolism (n = 1) and lung 
neoplasm (n = 1).
In the year prior to the study, the use of health care 
resources was ≥ 1 visit only in the very severe group, 
compared with the moderate and severe groups, as assessed 
by the number of visits to the emergency room (Table 1). 
Similarly, the very severe group tended to receive a greater 
number of prescribed antibiotic or oral steroid courses 
during the previous year than either of the other 2 severity 
groups.
Discussion
This analysis of this study population demonstrates that 
dyspnoea was the most frequently reported symptom 
leading to the diagnosis of COPD at all stages of the disease 
and was also the most troublesome symptom at all levels 
of severity. These findings are consistent with previous 
experience that dyspnoea is usually the fi rst symptom that 
causes a patient to seek medical attention. 8 By contrast, 
although cough is usually the fi rst symptom to develop, it 
is often overlooked by patients. 8 The reports of dyspnoea 
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increased with increasing disease severity. These results 
suggest that dyspnoea should be considered as a diagnostic 
marker of COPD, even at less severe or moderate stages. As 
dyspnoea was the most troublesome symptom for patients 
with COPD, it should also be a primary treatment outcome.
It should be noted that cough, the main symptom leading 
to diagnosis in patients with moderate COPD, became a 
relatively less troublesome symptom with increasing disease 
severity, in contrast with dyspnoea, which increased in all 
severity groups.
Similar findings have been reported in the literature. 
A telephone survey of patients with COPD living in North 
America and in Europe documented the frequency of 
breathlessness with daily activities. 9 According to this 
survey, one-fifth of patients reported that they were 
breathless, even when just sitting or lying still, and 24 % 
when talking. One-third said they were breathless when 
doing light housework or while getting washed or dressed, 
and nearly 70 % were short of breath when walking up 
a fl ight of stairs. It is clear from these data that COPD is 
associated with a considerable burden of disease, affecting 
many activities that are fundamental to everyday life, such 
as the ability to breathe, talk, work, sleep, have sexual 
activity and socialise. However, in the same study, 9 COPD 
patients also regarded their disease as mild to moderate, 
despite suffering from relatively severe dyspnoea. 
This latter finding highlights the difficulties inherent in 
diagnosing COPD on symptomatic grounds. The condition 
is often under-diagnosed, at least partly because patients 
do not recognise relevant symptoms. 10 The diagnosis of 
COPD should be considered in any patient who presents 
with cough, dyspnoea or sputum production, particularly if 
the patient has been exposed to risk factors. 8,11 The best 
established risk factor for COPD is exposure to tobacco 
smoke; 8 epidemiological studies have shown that, with 
suffi cient exposure, most smokers will eventually develop 
airfl ow limitation. 12 Hence, a positive smoking history was 
an inclusion criterion in the present study. Other risk factors 
include indoor air pollution, occupational exposure to dust, 
gases or fumes and genetic infl uences. 8
The patients participating in this study had moderate or 
severe COPD, and were being treated in specialised centres. 
This raises the question as to the extent the fi ndings are 
generalisable to the general population. In fact, because 
the patients were selected from specialised pulmonology 
services, they correspond to a subgroup of COPD patients 
and are not completely representative of the real life COPD 
patients. Accordingly, the extremely high prevalence of 
males (96 %) may result from this selection.
Akamatsu et al have reported that symptoms alone have a 
low sensitivity for the diagnosis of COPD, and recommended 
that the diagnosis be confirmed by spirometry. 13 Other 
studies, however, have shown that the use of symptom-based 
questionnaires to diagnose COPD is feasible in the general 
population. In one study, a questionnaire based on age, 
symptoms (wheezing and sputum production), smoking 
history, BMI and previous diagnosis of obstructive lung 
disease achieved a sensitivity of 85 % and a specificity of 
45 %; 10 this performance was comparable with that of other 
instruments designed for use in a general population. 14 In 
our study, dyspnoea was the principal symptom leading to a 
diagnosis of COPD. By contrast, in a general practice study 
in Netherlands, chronic cough had the strongest predictive 
value for COPD among smokers. 15 However, it should be 
noted that, in this study, from a population of 169 smokers 
only 30 had airways obstruction; in addition, the obstruction 
criterion was FEV1 < 80 % of predicted normal values, 
allowing the inclusion of patients with less severe disease 
than in the current study (FEV1 ≤ 70 % of predicted normal 
values).
Despite dyspnoea and cough being good predictors of 
COPD, current guidelines recommend that spirometry is 
needed to confi rm the diagnosis in patients in whom COPD 
is suspected on symptomatic grounds and encourage the use 
of spirometry in primary care. 3,11
Somehow unexpected was the finding of only 5 % of 
patients reported sputum production as the fi rst symptom 
that led to COPD diagnosis. One explanation for this result 
could be memory bias, taking into account that mean 
disease duration at the time of evaluation was 14.4 years.
Another issue in our study is the large group of 
co-morbidities associated with COPD. It is possible that, 
in some cases these may have introduced confounding 
effect by producing symptoms that overlap with those of 
COPD. In particular, respiratory disorders were reported 
in 14 % of patients, and in the majority of the cases these 
could be considered complications of COPD. However, 
this interpretation requires caution. Although pneumonia 
is a common feature of COPD exacerbations, there are 
important differences between exacerbations with and 
without pneumonia; patients with pneumonia tend to show 
a faster onset of symptoms, and more severe illness, than 
those without. 16,17 Although dyspnoea could be a symptom of 
congestive heart failure as well as COPD, it seems unlikely 
that this was a major confounding factor in this study 
because only 19 patients (6.4 %) had diagnoses of heart 
failure.
There is extensive evidence that co-morbidities are 
common among patients with COPD, although the reported 
prevalence vary widely. 17-26 There is, for example, a 
growing body of epidemiological evidence linking COPD 
with cardiovascular disease. 21,22 Large population-based 
studies suggest that patients with COPD have 2 to 3 times 
the risk for cardiovascular mortality compared with 
controls. 21-24 The profi le of co-morbidities seen in our study 
was consistent with that reported in other studies. 17,18,26 
Moreover, considering that some exclusion criteria were 
related to the presence of some co-morbidity, the reported 
co-morbidities may underestimate their real occurrence. 
In accordance with our results, Antonelli Incalzi et al, 25 
in a study of 270 COPD patients discharged from hospital 
after an acute exacerbation of COPD, found that the most 
common co-morbid conditions were hypertension (28 %), 
diabetes mellitus (14 %) and ischemic heart disease (10 %). 
Also, in a review of the literature, Chatila et al 17 reported 
that cardiovascular disorders are present in 13-65 % of 
COPD patients, hypertension in 18-52 %, diabetes mellitus 
in 5-16 % and gastrointestinal disorders in 15-62 %. More 
recently Agusti et al, 26 in the description of the Eclipse 
cohort, reported higher prevalence of co-morbidities in 
COPD patients than in controls and with similar frequencies 
to our data.
This increased prevalence of co-morbidities in COPD may 
provide an opportunity to efficiently identify persons at 
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risk for undiagnosed COPD and to get them appropriately 
evaluated, diagnosed and treated.
The fi ndings of the present study highlight the importance 
of the association between dyspnoea and co-morbidities 
when considering a diagnosis of COPD. The authors suggest 
that, mainly in the primary care setting and internal 
medicine outpatient clinics where patients presenting 
with dyspnoea associated with co-morbid conditions such 
as cardiovascular disease, peptic disease and/or diabetes 
mellitus, are frequent, the diagnosis of COPD should be 
considered. As a consequence, a spirometry should be done 
in order to exclude a diagnosis of COPD.
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